Functional genomics

Genomics Market to Reach $94.86 Billion by 2030 at CAGR 16.5%: Grand View Research, Inc.

Retrieved on: 
Wednesday, April 19, 2023
Metagenomics, Survivor, CRISPR, Molecular epidemiology, Chromosome, Therapy, SARS-CoV-2, Genomics, National Centre for Disease Control, University of Cambridge, NGS, IHOP, National Cancer Institute, Pathway analysis, Inherited disorders of trafficking, Research, Genetic Alliance, Infection, OGL, DSM-IV codes, Biomarker, USD, Government, CDC, Whole genome sequencing, Revenue, Nature, SAN, Biomarker discovery, Functional genomics, Cancer, Merck & Co., Rare, Gene, Genetic disorder, Disease, Illumina, Inc., Antibiotics, Vaccine, Epigenomics

SAN FRANCISCO, April 19, 2023 /PRNewswire/ -- The global genomics market size is expected to reach USD 94.86 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, April 19, 2023 /PRNewswire/ -- The global genomics market size is expected to reach USD 94.86 billion by 2030, according to a new report by Grand View Research, Inc.
  • The market is expected to register a CAGR of 16.5% in the forecast period owing to the increasing demand for novel therapeutic and research applications in genomics.
  • Read full market research report more latest industry insights, " Genomics Market Size, Share & Trends Analysis Report By Technology & Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery), By Deliverables, End-use, By Region, And Segment Forecasts, 2023 - 2030 ", published by Grand View Research.
  • Grand View Research has segmented the global genomics market on the basis of application, deliverables, end-use, and region
    Genomics Market - Application & Technology Outlook (Revenue, USD Million, 2018 - 2030)

Genomics Global Market Report 2022: Increasing Demand for Novel Therapeutics Drives Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022
Biotechnology, Genetics, Health, Genetic Alliance, Genetic disorder, Genomics, Molecular epidemiology, Infection, IHOP, Government, CDC, Cancer, Severe acute respiratory syndrome coronavirus 2, National Cancer Institute, University of Cambridge, Survivor, Biomarker, Functional genomics, USD, Biomarker discovery, Research, CRISPR, Pathway analysis, Nature, Chromosome, Metagenomics, National Centre for Disease Control, Disease, Whole genome sequencing, Therapy, Degenerative disease, Inherited disorders of trafficking, NGS, Illumina, Inc., Merck & Co., OGL, Gene, Antibiotics, Epigenomics

The "Genomics Market Size, Share & Trends Analysis Report by Technology & Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery), by Deliverables, End Use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genomics Market Size, Share & Trends Analysis Report by Technology & Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery), by Deliverables, End Use, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global genomics market size is expected to reach USD 94.9 billion by 2030.
  • The market is expected to register a CAGR of 16.4% in the forecast period owing to the increasing demand for novel therapeutics and research applications in genomics.
  • Functional genomics held the largest market share in the year 2021, owing to the demand for rising applications in diagnostics and gene therapy.

LifeMine Therapeutics and GSK Enter Drug Discovery and Development Alliance

Retrieved on: 
Wednesday, March 23, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Company, GEM, Therapy, GSK, Fungus, Partnership, Data science, Genetics, IND, Gemstone, Genomics, Probability, Stage Fort across Gloucester Harbor, SVP, Functional genomics, Biotransformation, GlaxoSmithKline, Machine learning, Chemistry, Drug discovery, File, Pharmaceutical industry

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced a strategic R&D collaboration with GlaxoSmithKline (GSK).

Key Points: 
  • LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced a strategic R&D collaboration with GlaxoSmithKline (GSK).
  • In addition, LifeMine is eligible to receive undisclosed discovery, development and commercial milestone payments for each collaboration product.
  • LifeMine will be also eligible to receive royalties on net sales of any drug from the collaboration that is commercialized by GSK.
  • Through its proprietary, evolutionarily-derived genomic drug discovery platform, LifeMine aims to bring unparalleled speed, predictability and scalability to small molecule drug discovery.

EMCORE Announces Definitive Agreement to Acquire the L3Harris Space and Navigation Business

Retrieved on: 
Tuesday, February 15, 2022
Quartz, Lithium, NYSE, Intellectual property, Fibre-optic gyroscope, CEO, Company, Certification, Forward-looking statement, Technology, Atmosphere, Functional genomics, AS9100, CA, Securities Act of 1933, Nasdaq, Annual report, GLOBE, Indium phosphide, Securities Exchange Act of 1934, Defense, Navigation, FOG, Risk, Acquisition, Lithium niobate, Senior, Engineering, Growth, Foot, Fog, COVID-19, General manager, Industry, Risk management, L3Harris Technologies, Space

L3Harris Space and Navigation designs and builds some of the most accurate Navigation products in the world.

Key Points: 
  • L3Harris Space and Navigation designs and builds some of the most accurate Navigation products in the world.
  • This is an excellent fit strategically for EMCORE, bringing Space and Navigations strong brand, inertial technology, and important program wins.
  • The L3Harris Space and Navigation team will provide EMCORE with the capability to accelerate expansion into a true navigation grade FOG business with superior performance and accuracy compared to competitors, commented Albert Lu, Senior Vice President and General Manager, Aerospace and Defense for EMCORE.
  • Such statements include statements regarding the anticipated benefits, including anticipated revenue, of EMCOREs acquisition of the Space and Navigation business from L3Harris Technologies, market trends and the anticipated relationship with L3Harris Technologies following the transaction.

Amgen Ventures Invests in TileDB to Advance Their Universal Database

Retrieved on: 
Thursday, January 20, 2022
Research, Technology, Finance, Professional Services, Software, Biotechnology, Health, Data Management, Science, Other Science, Cloud, Functional genomics, Genomics, HPC, Table, CEO, Solution, Health care, Language, Economics, Therapy, Medicine, Drug discovery, Computer data storage

TileDB, Inc. a pioneering database company, announced today a strategic investment from Amgen Ventures, joining recent strategic investments from Lockheed Martin Ventures and NTT Docomo Ventures .

Key Points: 
  • TileDB, Inc. a pioneering database company, announced today a strategic investment from Amgen Ventures, joining recent strategic investments from Lockheed Martin Ventures and NTT Docomo Ventures .
  • The funding will be used to advance the vision and development of the TileDB universal database.
  • TileDB includes TileDB Embedded , an open-source storage engine for arrays, and TileDB Cloud , a universal database that offers secure governance, access management, scalable compute and sharing so researchers and clinicians can easily discover and explore datasets of interest, as well as reproduce findings.
  • Established in 2004 as Amgens Corporate Ventures Fund, Amgen Ventures identifies and invests in emerging companies and technologies to advance promising new medicines and solutions to healthcares biggest challenges.

BridGene Biosciences Announces Research Collaboration with the Peter MacCallum Cancer Centre to Discover Targets and Small Molecule Drug Candidates for Ovarian Cancer

Retrieved on: 
Wednesday, December 15, 2021
Food, FDA, Protein, History, Education, Functional genomics, Andrew Bridgen, Genomics, SAN, IND, Science, Drug discovery, Cancer, Phenotype, CEO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Biotechnology, Patient, Disease, Drug development, Associate, TDD, Peter MacCallum Cancer Centre, Ovarian cancer, Peter Mac Manu, PDD, Pharmaceutical industry

Under the collaboration, Peter Mac and BridGene will establish a drug discovery program harnessing Peter Mac's ovarian chemoresistance phenotypic screening and BridGene's proprietary IMTAC (Isobaric Mass Tagged Affinity Characterization) Chemoproteomics platform to discover new targets and small molecule drug candidates for the treatment of chemoresistant ovarian cancer.

Key Points: 
  • Under the collaboration, Peter Mac and BridGene will establish a drug discovery program harnessing Peter Mac's ovarian chemoresistance phenotypic screening and BridGene's proprietary IMTAC (Isobaric Mass Tagged Affinity Characterization) Chemoproteomics platform to discover new targets and small molecule drug candidates for the treatment of chemoresistant ovarian cancer.
  • BridGene will have exclusive rights to develop and commercialize the drug candidates that emerge from the research program.
  • "This collaboration with researchers at Peter Mac represents an important milestone for BridGene to develop a novel drug discovery strategy, that combines phenotypic drug discovery (PDD) and target-based drug discovery (TDD).
  • The Peter MacCallum Cancer Centre (Peter Mac) is a world leading cancer research, education and treatment center and Australia's only public health service solely dedicated to caring for people affected by cancer.

Scientific Leader Xiaokui Zhang, Ph.D. Joins Aspen Neuroscience as Chief Scientific Officer

Retrieved on: 
Thursday, November 18, 2021
Patient, Cell, Lists of diseases, IPSC, STEM, Regeneration, CMC, PD, Secondary research, Industry, Brain, Publication, Nanjing University, Research and development, Executive, Genomics, Instituto de Biologia Molecular e Celular, QC, Novartis, Functional genomics, SAN, ISCT, Woman, Helicon, Research, Investment, Artificial intelligence, National university, Parkinson's disease, Regenerative medicine, Rockefeller University, Medicine, Therapy, Cell biology, Multimedia, International Society, Pharmaceutical industry, Management, Medical device

"As Aspen grows, we are excited to welcome Dr. Zhang," said Damien McDevitt, Ph.D., Aspen Neuroscience president and chief executive officer.

Key Points: 
  • "As Aspen grows, we are excited to welcome Dr. Zhang," said Damien McDevitt, Ph.D., Aspen Neuroscience president and chief executive officer.
  • "The next frontier in medicine is at the intersection of autologous, personalized medicine for every patient," said Dr. Zhang.
  • I am honored and excited for this rare opportunity to lead the next stage of Aspen's scientific vision."
  • Headquartered in San Diego, Aspen Neuroscience, Inc. is a development stage, private biotechnology company focused on personalized (autologous) cell therapies.

Global Genomics Market Research Report 2021: Focus on Functional Genomics & Pathway Analysis - Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 14, 2021
Health, Genetics, Degenerative disease, Technology, Diabetes, Product, Severe acute respiratory syndrome coronavirus 2, CGH, Genome, Solution, Awareness, Cepheid variable, Biomedical Research, Gene, Adoption, Lists of diseases, Cancer, Breast cancer, Cepheid (company), Veritas Genetics, Academic health science centre, Efficiency, Data management, DNA, Karyotype, Patient, PCR, 23andMe, Functional genomics, COG-UK, NGS, COVID-19 Genomics UK Consortium, Biotechnology, Pathway analysis, Prognosis, Quest Diagnostics, COVID-19, Application, Genomics, Asia-Pacific, Thermo Fisher Scientific, Catalog, Consortium, Antibiotics, Vaccine, Animal

The "Global Genomics Market Size, Share & Trends Analysis Report by Application & Technology (Functional Genomics, Pathway Analysis), by Deliverable (Products, Services), by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genomics Market Size, Share & Trends Analysis Report by Application & Technology (Functional Genomics, Pathway Analysis), by Deliverable (Products, Services), by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • This has also led to an increase in the market competition, coupled with the development of breakthrough genomic technologies by Veritas Genetics, 23andMe, and other key players.
  • In August 2020, Ancestry launched a new next-generation sequencing-based tool to screen genes linked to blood disorders, colon cancer, heart diseases, and breast cancer.
  • This product, developed by Quest Diagnostics, has a better DNA analysis efficiency when compared to microarray-based testing.

ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in September and October

Retrieved on: 
Wednesday, September 22, 2021
ISIN, Person, Conference, Precision medicine, Structure, Spanish, PMS, Communication, Genomics, Kabuki syndrome, HOPE, EST, Safety, ORY, Public expenditure, Research, Mercado, BPD, BIO, Hospital Universitario La Paz, Development of the nervous system, Prospectus, Phenotype, Borderline personality disorder, CNS, Clinical trial, RRMS, Patient, ECNP, Pediatrics, Sale, CNMV, Neuroscience, Hospital das Clínicas, Functional genomics, SPMS, Forward-looking statement, LSD1, Kennedy Krieger Institute, GLOBE, Department, Treatment, KOL, European Committee for Sports History, Assistant, Congress, Central nervous system disease, Mission statement, Sclerosis (medicine), Psychiatry, Degeneration theory, International Conference on Nuclear Disarmament, Oslo, 2008, CET, Schizophrenia, Pharmaceutical industry, Medical device

Oryzon will present preliminary data from the ongoing collaboration with INGEMM in Phelan McDermid Syndrome (PMS) at the International Conference on Autism, ICA-2021, which will be held on September 23-24.

Key Points: 
  • Oryzon will present preliminary data from the ongoing collaboration with INGEMM in Phelan McDermid Syndrome (PMS) at the International Conference on Autism, ICA-2021, which will be held on September 23-24.
  • The communication entitled "Phenotype and Psychometric Characterization of Phelan McDermid Syndrome Patients" will be presented by Dr. Carlos Buesa, Oryzons CEO.
  • Executive directors of the company will attend the BIO Spain 2021 event, which will take place September 27-October 1.
  • The company will moderate a KOL panel discussion on precision medicine therapeutic approaches for CNS disorders and the potential of LSD1 inhibitors like vafidemstat.

Dovetail Genomics Announces New Capture Hi-C Targeted Enrichment Panels

Retrieved on: 
Wednesday, June 16, 2021
Branches of biology, Biology, Genetics, Genomics, Nuclear organization, Molecular biology, Omics, Chromosome conformation capture, Biotechnology, DNA sequencing, Functional genomics

Genome-wide Hi-C studies have been highly informativein defining thecritical relationship between chromosome architecture and gene expression.However, the sequencingdepthrequired can be asignificantbarrier tolarger studies.

Key Points: 
  • Genome-wide Hi-C studies have been highly informativein defining thecritical relationship between chromosome architecture and gene expression.However, the sequencingdepthrequired can be asignificantbarrier tolarger studies.
  • Dovetail'snew productsreduce the sequencing burden byover90%, enabling interactions between promoters and their regulatory elements to be studied at a fraction of the cost.
  • In addition, the targeted approach increasesthesensitivity and resolution of the assay.
  • Dovetail Genomics LLC is transforming genomics by making long-range information readily accessible to all.